Q-omics provides the consensus-scored TTC7B profile across patient tissues and cancer cell-line models. TTC7B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TTC7B is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, TTC7B protein abundance shows 27,712 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, and GBM as cancer lineages where TTC7B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTC7B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTC7B survival associations across molecular data types. TTC7B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTC7B RNA expression–survival associations across cancer types. High TTC7B expression shows unfavorable associations in HNSC, BLCA, ACC and LUSC, but favorable associations in KIRC and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TTC7B RNA expression.
This table summarizes TTC7B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TTC7B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTC7B shows lower tumor expression in LUAD, BRCA, THCA and KIRC and higher tumor expression in HNSC and KICH. The HNSC box plot shows higher TTC7B RNA expression in tumor versus normal tissue (log2 FC = +1.234, t-test p < 0.001).
This table shows molecular features associated with TTC7B in patient tissues and cancer cell lines. In patient samples, TTC7B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TTC7B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
